Literature DB >> 31179517

Cost-effectiveness of coronary artery bypass graft and percutaneous coronary intervention compared to medical therapy in patients with coronary artery disease: a systematic review.

Saeed Sheikh Gholami1, Farbod Ebadi Fard Azar2, Aziz Rezapour3, Masih Tajdini4.   

Abstract

Coronary artery disease (CAD) has significant social and economic implications. It is necessary to create tools to identify the most cost-effectiveness treatments, which can assist clinicians in their therapeutic decisions so that the maximum possible benefit is reached with the lowest possible cost. Effectiveness must be measured by final treatment goals in which the most effective interventions are those with the lowest costs. This study is aimed to systematically review and compare the studies conducted on the cost-effectiveness of the three coronary artery disease treatment strategies (medical treatment, percutaneous coronary intervention, and coronary artery bypass graft). In this systematic review, the databases NHS Economic Evaluation Database, Embase, MEDLINE, Science Direct, and Scopus were searched for studies on the cost-effectiveness of coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI) compared to medical therapy (MT) in patients with coronary artery disease between 1 January 2004 to 30 September 2018. The quality appraisal of the included studies was examined using the Consolidated Health Economics Evaluation Reporting Standards (CHEERS) statement. Out of 186 unique retrievals, 8 studies were included. The results showed that the all studies clearly stated the time horizon of the study and included direct medical costs in their analysis. In addition, in most of the studies, quality-adjusted life years (QALY) were the main outcome used for measuring the effectiveness. The studies reported various ranges of the incremental cost-effectiveness ratio (ICER); accordingly, the highest ratio was observed in the USA ($212,800) for PCI v MT and the lowest ratio was observed in Brazil ($4403) for CABG v MT. Although the results of the studies were different in terms of a number of aspects, such as the viewpoint of the study, the study horizons, and the costs of expenditure items, they reached similar results. Based on the result of the present study, it seems that each three treatment strategies for CAD yielded improvements in QALY.

Entities:  

Keywords:  Coronary artery bypass graft; Coronary artery disease; Cost-effectiveness; Economic evaluation; Medical therapy; Percutaneous coronary intervention

Mesh:

Year:  2019        PMID: 31179517     DOI: 10.1007/s10741-019-09811-3

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  25 in total

1.  Sensitivity analysis for handling uncertainty in an economic evaluation.

Authors:  Supon Limwattananon
Journal:  J Med Assoc Thai       Date:  2014-05

2.  Coronary Artery Surgery Study (CASS): comparability of 10 year survival in randomized and randomizable patients.

Authors:  B R Chaitman; T J Ryan; R A Kronmal; E D Foster; P L Frommer; T Killip
Journal:  J Am Coll Cardiol       Date:  1990-11       Impact factor: 24.094

3.  Factors affecting the technical efficiency of health systems: A case study of Economic Cooperation Organization (ECO) countries (2004-10).

Authors:  Ramin Ravangard; Nahid Hatam; Abedin Teimourizad; Abdosaleh Jafari
Journal:  Int J Health Policy Manag       Date:  2014-06-08

4.  Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease.

Authors:  Whady Hueb; Neuza Helena Lopes; Bernard J Gersh; Paulo Soares; Luiz A C Machado; Fabio B Jatene; Sergio A Oliveira; Jose A F Ramires
Journal:  Circulation       Date:  2007-03-06       Impact factor: 29.690

5.  Health service costs of coronary angioplasty and coronary artery bypass surgery: the Randomised Intervention Treatment of Angina (RITA) trial.

Authors:  M J Sculpher; P Seed; R A Henderson; M J Buxton; S J Pocock; J Parker; M D Joy; E Sowton; J R Hampton
Journal:  Lancet       Date:  1994-10-01       Impact factor: 79.321

Review 6.  Growing epidemic of coronary heart disease in low- and middle-income countries.

Authors:  Thomas A Gaziano; Asaf Bitton; Shuchi Anand; Shafika Abrahams-Gessel; Adrianna Murphy
Journal:  Curr Probl Cardiol       Date:  2010-02       Impact factor: 5.200

7.  Cost-effectiveness of B-type natriuretic peptide-guided care in patients with heart failure: a systematic review.

Authors:  Abdosaleh Jafari; Aziz Rezapour; Marjan Hajahmadi
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

8.  Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study.

Authors:  S C Griffin; J A Barber; A Manca; M J Sculpher; S G Thompson; M J Buxton; H Hemingway
Journal:  BMJ       Date:  2007-03-05

9.  Effectiveness of revascularization interventions compared with medical therapy in patients with ischemic cardiomyopathy: A systematic review protocol.

Authors:  Aziz Rezapour; Saeed Bagheri Faradonbeh; Vahid Alipour; Mani Yusefvand
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889

10.  Cost-Utility Analysis of IEV Drug Regimen Versus ESHAP Drug Regimen for the Patients With Relapsed and Refractory Hodgkin and Non-Hodgkin's Lymphoma in Iran.

Authors:  Nahid Hatam; Mehdi Dehghani; Mostafa Habibian; Abdosaleh Jafari
Journal:  Iran J Cancer Prev       Date:  2015-10-27
View more
  1 in total

1.  Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Medicine in Ischemic Cardiomyopathy: The STICH Randomized Clinical Trial.

Authors:  Derek S Chew; Patricia A Cowper; Hussein Al-Khalidi; Kevin J Anstrom; Melanie R Daniels; Linda Davidson-Ray; Yanhong Li; Robert E Michler; Julio A Panza; Ileana L Piña; Jean L Rouleau; Eric J Velazquez; Daniel B Mark
Journal:  Circulation       Date:  2022-01-19       Impact factor: 29.690

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.